

# International Collaborative Ovarian Neoplasm studies (2): a trial of CAP versus carboplatin in advanced ovarian cancer

|                                        |                                                   |                                                                                                   |
|----------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>28/02/2001   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol            |
| <b>Registration date</b><br>28/02/2001 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results |
| <b>Last Edited</b><br>09/07/2014       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data                                              |

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Ms Claire Amos

### Contact details

MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

### Protocol serial number

ICON2

## Study information

### Scientific Title

### Study objectives

To compare cyclophosphamide, doxorubicin and cisplatin (CAP) with single-agent carboplatin in patients with advanced ovarian cancer.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Primary study design**

Interventional

**Study design**

Randomised controlled trial

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Ovarian cancer

**Interventions**

1. Cyclophosphamide, doxorubicin and cisplatin (CAP)
2. Single-agent carboplatin

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Cyclophosphamide, doxorubicin, cisplatin, carboplatin

**Primary outcome(s)**

1. Survival time
2. Progression-free survival

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/1996

**Eligibility**

**Key inclusion criteria**

1. Chemotherapy indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Female

**Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

01/01/1991

**Date of final enrolment**

31/12/1996

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

Medical Research Council (MRC) (UK)

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (MRC) (UK)

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 14/11/1998   |            | Yes            | No              |